Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Gastrointestinal 3Plasma cell 2Other hematologic neoplasm 2CNS 2Sarcoma 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Carcinoma, Basal Cell 4Basal Cell Nevus Syndrome 3Skin Neoplasms 2Hematologic Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1

Interventions

Ipilimumab 101pembrolizumab 94Nivolumab 87Cyclophosphamide 69fludarabine phosphate 55aldesleukin 52Interleukin-2 39Dacarbazine 35Vemurafenib 31fludarabine 30trametinib 29dabrafenib 29Temozolomide 28Whole-Body Irradiation 21Aminolevulinic Acid 21Carboplatin 20CTLA-4 Antigen 20Bevacizumab 20Radiotherapy 19Peripheral Blood Stem Cell Transplantation 19Radiosurgery 18Tacrolimus 17Mycophenolic Acid 17Paclitaxel 16HhAntag691 163-ingenyl angelate 16Busulfan 15Introns 14Antilymphocyte Serum 14encorafenib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × sonidegib × Dermatologic × Clear all
NCT01327053 2019-08-28

BOLT

Novartis

Phase 2 Completed
230 enrolled 26 charts
Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms

NCT02303041 2019-01-29

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

Stanford University

Phase 2 Terminated
10 enrolled 11 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Skin Neoplasms

NCT01529450 2017-01-16

Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors

Stanford University

Phase NA Completed
11 enrolled 10 charts
Dermatologic

Carcinoma, Basal Cell

NCT02002689 2016-05-02

SIGNATURE

Novartis

Phase 2 Terminated
10 enrolled 9 charts
DermatologicGastrointestinalGynecologicOther hematologic neoplasm

Basal Cell Nevus Syndrome, Colonic Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT01350115 2015-10-19

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Novartis

Phase 2 Completed
10 enrolled 9 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡